July 26, 2023
SAN RAMON, Calif. — The World Society of Paediatric Ophthalmology and Strabismus (WSPOS) has translated its Myopia Consensus Statement into multiple languages.
CooperVision worked with the organization to translate the document into three languages: Portuguese, Spanish, and French. Additional language translations still to come include Arabic, Indonesian, Ukrainian, Hindi, Hungarian, Polish, Filipino, Romanian, Hindi, Telugu, Odia, Mandarin, Simplified Chinese, and Japanese.
The consensus statement concludes that there is “sufficient evidence to warrant the adoption of myopia prevention and control measures in clinical practice in children with progressive myopia.”
“We recognize the significance of the WSPOS Myopia Consensus Statement to raise awareness and drive urgency for treating myopia among ophthalmologists. Translating these statements will help expand professional knowledge and treatment around the world,” said Elizabeth Lumb, BSc (Hons) MCOptom, FBCLA, Director of Global Professional Affairs, Myopia Management, CooperVision.
The WSPOS guidance is based on studies that have demonstrated both statistical and clinical significance in the effectiveness of slowing myopia progression, with all listed interventions having at least two years of peer-reviewed data. In referring to MiSight 1 day, the authors share highlights from the landmark long-term, international MiSight 1 day clinical trial to convey its efficacy, including children aged 8 to 12 at the initiation of treatment showed a 59% on average reduction in rate of myopia progression over a three-year period, compared to single vision contact lenses.1†
Lumb added, “In addition to its latest guidance, the WSPOS has begun an Independent Medical Educational series on myopia, made possible in part through a CooperVision grant. Past webinars are available on demand at forum.wspos.org/myopia-
† Compared to a single vision 1-day lens over a 3-year period.
1 Chamberlain P, Peixoto-de-Matos SC, Logan NS, Ngo C, Jones D, Young G. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. Optom Vis Sci. 2019 Aug;96(8):556-567.